IPP Bureau
Aurobindo Pharma’s subsidiary acquires Ace Laboratories, UK
By IPP Bureau - June 29, 2024
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch
By IPP Bureau - June 28, 2024
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Eugia SEZ’s injectable facility gets EIR from USFDA
By IPP Bureau - June 28, 2024
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
ANG Lifesciences India updates on acquisition of unit from Ind-Swift
By IPP Bureau - June 28, 2024
This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres
Pfizer and BioNTech receive Positive CHMP opinion for Omicron JN.1-adapted COVID-19 vaccine in EU
By IPP Bureau - June 28, 2024
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Sanofi Consumer Healthcare India appoints Himanshu Bakshi as MD
By IPP Bureau - June 27, 2024
Himanshu brings with him a wealth of rich experience from commercial, marketing, and general management roles
.jpg "Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India")
Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India
By IPP Bureau - June 27, 2024
Glenmark released Picture Post Cards on World Vitiligo Day
Aster DM Healthcare achieves NABH Digital Standards' Platinum Certification for Aster CMI Hospital
By IPP Bureau - June 27, 2024
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Shilpa Medicare Bio Analytical unit gets "No Action Indicated" classification from USFDA
By IPP Bureau - June 27, 2024
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
CCRAS hosts national consultative meet on traditional medicine
By IPP Bureau - June 26, 2024
Signs MoUs with Shri Krishna Ayush University and Dabur India
Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
By IPP Bureau - June 26, 2024
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Imfinzi improved event-free survival and overall survival for bladder cancer
By IPP Bureau - June 26, 2024
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
USDA approves Merck Animal Health’s NOBIVAC NXT canine flu H3N2
By IPP Bureau - June 26, 2024
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Lupin receives EIR from US FDA for its Somerset manufacturing facility
By IPP Bureau - June 25, 2024
The facility was inspected from May 7 to May 17, 2024
